Relmada Therapeutics, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging -0.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.21 | $-0.11 | +47.6% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.18 | $-0.22 | -22.2% | Miss | Q1 FY26 call |
| Q4 FY25 | $-0.14 | $-0.27 | -92.9% | Miss | Q4 FY25 call |
| Q3 FY25 | not reported | $-0.30 | not reported | not reported | Q3 FY25 call |
| Q2 FY25 | $-0.25 | $-0.30 | -20.0% | Miss | Q2 FY25 call |
| Q1 FY25 | not reported | $-0.58 | not reported | not reported | |
| Q4 FY24 | $-0.70 | $-0.62 | +11.4% | Beat | |
| Q3 FY24 | $-0.65 | $-0.72 | -10.8% | Miss | |
| Q2 FY24 | $-0.83 | $-0.59 | +28.9% | Beat | |
| Q1 FY24 | $-0.90 | $-0.72 | +20.0% | Beat | |
| Q4 FY23 | $-0.88 | $-0.84 | +4.5% | Beat | |
| Q3 FY23 | $-0.95 | $-0.73 | +23.2% | Beat |
Back to RLMD overview · RLMD holders · RLMD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.